Hammarsten Peter, Dahl Scherdin Tove, Hägglöf Christina, Andersson Pernilla, Wikström Pernilla, Stattin Pär, Egevad Lars, Granfors Torvald, Bergh Anders
Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
PLoS One. 2016 Oct 20;11(10):e0164016. doi: 10.1371/journal.pone.0164016. eCollection 2016.
In the present study we have investigated whether Caveolin-1 expression in non-malignant and malignant prostate tissue is a potential prognostic marker for outcome in prostate cancer patients managed by watchful waiting. Caveolin-1 was measured in prostate tissues obtained through transurethral resection of the prostate from 395 patients diagnosed with prostate cancer. The majority of the patients (n = 298) were followed by watchful waiting after diagnosis. Tissue microarrays constructed from malignant and non-malignant prostate tissue were stained with an antibody against Caveolin-1. The staining pattern was scored and related to clinicopathologic parameters and outcome. Microdissection and qRT-PCR analysis of Cav-1 was done of the prostate stroma from non-malignant tissue and stroma from Gleason 3 and 4 tumors. Cav-1 RNA expression was highest in non-malignant tissue and decreased during cancer progression. High expression of Caveolin-1 in tumor stroma was associated with significantly longer cancer specific survival in prostate cancer patients. This association remained significant when Gleason score and local tumor stage were combined with Caveolin-1 in a Cox regression model. High stromal Caveolin-1 immunoreactivity in prostate tumors is associated with a favourable prognosis in prostate cancer patients managed by watchful waiting. Caveolin-1 could possibly become a useful prognostic marker for prostate cancer patients that are potential candidates for active surveillance.
在本研究中，我们调查了非恶性和恶性前列腺组织中Caveolin-1的表达是否是接受观察等待治疗的前列腺癌患者预后的潜在标志物。对395例经诊断患有前列腺癌的患者经尿道前列腺切除术后获得的前列腺组织进行Caveolin-1检测。大多数患者（n = 298）在诊断后接受观察等待。用抗Caveolin-1抗体对由恶性和非恶性前列腺组织构建的组织微阵列进行染色。对染色模式进行评分，并与临床病理参数和结果相关联。对非恶性组织的前列腺基质以及Gleason 3级和4级肿瘤的基质进行Cav-1的显微切割和qRT-PCR分析。Cav-1 RNA表达在非恶性组织中最高，并在癌症进展过程中降低。肿瘤基质中Caveolin-1的高表达与前列腺癌患者显著更长的癌症特异性生存期相关。当在Cox回归模型中将Gleason评分和局部肿瘤分期与Caveolin-1结合时，这种关联仍然显著。前列腺肿瘤中高基质Caveolin-1免疫反应性与接受观察等待治疗的前列腺癌患者的良好预后相关。Caveolin-1可能成为潜在适合积极监测的前列腺癌患者的有用预后标志物。
